ClinicalTrials.gg
RecruitingNCT06480019Updated Apr 13, 2026

IPT-based Group Intervention by Non-specialist for Improvement of Depressive Symptoms in Community Young Adults in Brazil

An interventional study of Interpersonal psychotherapy in Depression and Interpersonal Relations, sponsored by Hospital de Clinicas de Porto Alegre. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Hospital de Clinicas de Porto Alegre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2024, registered Jun 2024).
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Depression by Hospital de Clinicas de Porto Alegre — 1 open to participants now, 2 under way, none of them phase 3. Depression · Hospital de Clinicas de Porto Alegre.

Planned enrollment
6th of 10
50 · median 55
Started
2024
the only one that year
No phase
8 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Depression by Hospital de Clinicas de Porto Alegre, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 8 with no phase, and was the 11th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

1 of the 11 studies in Depression by Hospital de Clinicas de Porto Alegre is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Depression by Hospital de Clinicas de Porto Alegre, or all of them as a file.
02

Study summary

Major depressive disorder is a highly prevalent, recurrent, and debilitating disease, the third cause of years of lost life in the world, and it may be the most common disease in 2030, according to the World Health Organization (WHO). Furthermore, it's also related to decreased quality of life and high mortality. Interpersonal psychotherapy (IPT) is a first-line treatment and can also be used for the prevention of depression.

This randomized controlled clinical trial is planned to have 50 participants randomized between an interventional and a control group (waiting list). Our study covers young adults (18 to 24 years old) with depression. Participants will be invited by social media to undergo treatment in an IPT group. The intervention group will be separated into groups with up to 10 participants, with a weekly meeting for eight weeks. The intervention will focus on interpersonal relationships within the model of IPT and will be held by a university student and a doctor trained in IPT.

03

Conditions studied

  • Depression
  • Interpersonal Relations

Browse trials for

04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Young adults (between 18 and 24 years old)
  • Young adults who work, live or study in Porto Alegre
  • PHQ ≥ 5 - without suicide ideation

Exclusion criteria

Exclusion Criteria:

  • Maniac or hypomanic episode
  • Psychotic Syndrome
  • Substance Abuse
  • Suicide Risk or Ideation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Intervention

    Participants that receive psychotherapy

    Behavioral: Interpersonal psychotherapy

  • No intervention
    Waiting list

    Participants that are waiting for intervention

Interventions

  • BehavioralInterpersonal psychotherapy

    Interpersonal psychotherapy is a first-line treatment and can also be used for the prevention of depression.

06

What researchers measure

Primary outcomes

  1. Hospital Anxiety and Depression Scale (HADS)

    The Hospital Anxiety and Depression Scale consists of 14 items, of which 7 assess anxiety and 7 assess depression. Each item is scored from 0 to 3, and each subscale has a maximum score of 21 points with higher scores indicating greater symptom severity.

    Time frame: Pre-treatment, Week 1 to 8

Secondary outcomes

  1. Patient Health Questionnaire-9

    The PHQ-9 is a self-administered instrument that quantitatively assesses the severity of depressive symptoms over the past two weeks. It consists of nine items corresponding to the diagnostic criteria for major depressive disorder in the DSM-IV. Each item is scored on a 4-point Likert scale (0 = not at all to 3 = nearly every day), resulting in a score ranging from 0 to 27.

    Time frame: Pre-treatment, Week 1 to 8

  2. Social support scale (MOS-SSS)

    The Medical Outcomes Study Social Support Survey (MOS-SSS) measures each individual's perceptions of personal support. The scale comprises five support factors (emotional, informational, material, affective, and positive social interaction). Higher scores indicate greater perceived support.

    Time frame: Pre-treatment, Week 1 to 8

  3. Quality of Life (WHOQOL-BREF)

    The WHOQOL-BREF is a scale with 26 items that measure quality of life. It includes two general items and 24 items representing four domains (physical, psychological, social relationships, and environmental).

    Time frame: Pre-treatment, Week 1 to 8

  4. Clinical Global Impression (CGI)

    The Clinical Global Impressions (CGI) scale is an instrument that enables clinicians to assess the overall severity of the illness, the change in clinical status over time, and the effectiveness of the intervention used. Its score can range from 1 (not ill) to 7 (extremely ill).

    Time frame: Pre-treatment, Week 1 to 8

  5. Beck Depression Inventory (BDI)

    It's a self-report instrument and assesses the presence and severity of depressive symptoms. It consists of 21 items describing cognitive, affective, and somatic manifestations of depression. Each item is scored in a Likert scale ranging from 0 to 3, varying from 0 to 63 points

    Time frame: Pre-treatment; Week 1-8

Other outcomes

  1. Resilience (CD-RISC-10)

    The 10-item Connor-Davidson Resilience Scale (CD-RISC-10) is an abbreviated version of the original 25-item scale. It measures the capacity to adapt physically, mentally, and spiritually to the circumstances imposed by life. The 10 items are scored from 0 to 4, yielding a total score from 0 to 40. Higher scores indicate higher levels of resilience.

    Time frame: Pre-treatment, Week 1 to 8

  2. Psychotherapy side effects (UE-ATR checklist)

    It allows finding, classifying and discriminating between undesirable effects, adverse reactions to treatment and side effects of psychotherapy, based on the assessment of possible domains of unwanted effects in severity and relationship with the treatment.

    Time frame: Week 1 to 8

  3. Childhood Trauma Questionnaire (CTQ)

    The Childhood Trauma Questionnaire is a retrospective self-report instrument designed to assess experiences of childhood abuse and neglect. It consists of 28 items scored on a 5-point Likert scale, measuring five domains of maltreatment: emotional abuse, physical abuse, sexual abuse, emotional neglect, and physical neglect.

    Time frame: Week 1

  4. Life Stressful Events Questionnaire

    It assesses through closed questions, with dichotomous answers (yes vs. no), covering stressful life events.

    Time frame: Week 1 to 8

  5. Attachment (RSQ)

    The Relationship Scales Questionnaire (RSQ) assesses attachment styles in interpersonal relationships. It consists of 30 items describing thoughts and feelings in close relationships. Respondents rate their agreement with each item on a 5-point Likert scale. It assesses attachment through 30 declarative statements that express feelings and thoughts related to close relationships with people.

    Time frame: Week 1 and 8

  6. Eysenck Personality Questionnaire-Revised (EPQR-A)

    It is a self-administered questionnaire composed of 24 items divided into four domains: the three dimensions of personality (neuroticism, extraversion, and psychoticism) and a validity scale (social desirability).

    Time frame: Pre-treatment; Week 1-8

07

Study locations

1 of 1 sites recruiting
  • Clinical Hospital for Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 33 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2024
First posted
Jun 28, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06480019
Responsible party
Neusa Sica da Rocha (Principal Investigator, Hospital de Clinicas de Porto Alegre) — Principal investigator
First posted
Jun 28, 2024
Start date
Mar 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

Neusa Sica da Rocha, PhD
Contact
nrocha@hcpa.edu.br
55(51) 3359-8000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion